Medical School, College of Medicine and Health, University of Exeter, Exeter, UK.
Departments of Psychiatry, Clinical Neurosciences, Community Health Sciences, and Pathology, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
Alzheimers Res Ther. 2022 Jan 5;14(1):2. doi: 10.1186/s13195-021-00949-7.
Late-life onset neuropsychiatric symptoms are established risk factors for dementia. The mild behavioral impairment (MBI) diagnostic framework was designed to standardize assessment to determine dementia risk better. In this Mini Review, we summarize the emerging clinical and biomarker evidence, which suggests that for some, MBI is a marker of preclinical Alzheimer's disease. MAIN: MBI is generally more common in those with greater cognitive impairment. In community and clinical samples, frequency is around 10-15%. Mounting evidence in cognitively normal samples links MBI symptoms with known AD biomarkers for amyloid, tau, and neurodegeneration, as well as AD risk genes. Clinical studies have found detectable differences in cognition associated with MBI in cognitively unimpaired people.
The emerging evidence from biomarker and clinical studies suggests MBI can be an early manifestation of underlying neurodegenerative disease. Future research must now further validate MBI to improve identification of those at the very earliest stages of disease.
老年期发病的神经精神症状是痴呆的既定危险因素。轻度行为障碍（MBI）诊断框架旨在标准化评估，以更好地确定痴呆风险。在本次迷你综述中，我们总结了新出现的临床和生物标志物证据，这些证据表明，对于某些人来说，MBI 是临床前阿尔茨海默病的标志物。主要内容：MBI 通常在认知障碍程度较高的人群中更为常见。在社区和临床样本中，其频率约为 10-15%。越来越多的认知正常样本中的证据将 MBI 症状与已知的 AD 生物标志物（淀粉样蛋白、tau 和神经退行性变）以及 AD 风险基因联系起来。临床研究发现，在认知未受损的人群中，与 MBI 相关的认知差异是可检测到的。
来自生物标志物和临床研究的新证据表明，MBI 可能是潜在神经退行性疾病的早期表现。现在，必须进行进一步的研究来验证 MBI，以提高对疾病早期阶段人群的识别。
